2022 AIM-HI Women’s Venture Competition Announced 6 Semi-Finalists!

Press Release

2022 AIM-HI Women’s Venture Competition Announced 6 Semi-Finalists!

The AIM-HI Accelerator Fund (AIM-HI) just announced 6 Semi-Finalists for the 2022 AIM-HI Women’s Venture Competition! These innovative oncology start-ups have been selected from an exceptional pool of applications submitted by women scientist-entrepreneurs worldwide.

The AIM-HI Women’s Venture Competition, now in its third year, provides funding, coaching, and networking opportunities to women-led oncology start-ups to address unmet medical needs. The chosen semi-finalists will advance to a Virtual Competition on May 31, 2022.

AIM-HI has an unparalleled vigorous review process to determine the most deserving winner with high patient impact. Our Selection and Judging Committees are comprised of world-class key opinion leaders, life sciences industry experts, investors, and entrepreneurs. The winner of the 2022 AIM-HI Women’s Venture Competition will receive $1 million in investment from AIM-HI and co-investors. The funding will accelerate the development of new effective cancer treatments on the path to clinical trials and, eventually, for a cure.

About the AIM-HI Accelerator Fund

The AIM-HI Accelerator Fund (AIM-HI) is an independent 501(C)(3) non-profit organization, established in 2019 with an initial grant from the National Foundation for Cancer Research, with the purpose to accelerate the translation of cancer drug discoveries by investing in seed-stage companies.

NFCR is proud to be a partner organization for AIM-HI’s Women Venture Competition, helping to support and amplify the contributions of women in the field of oncology.

This article originally appeared on https://aim-hiaccelerator.org/. You can support their work here, and your gifts will empower women leaders who are creating life-saving oncology innovations!